Opportunities to Engage With the FDA About Qualification During Biomarker Development
Hello. I’m Dr. Kylie Haskins with the FDA’s Center for Drug Evaluation and Research, also known as CDER.
In this module, I will highlight some of the many opportunities that biomarker developers interested in qualifying a biomarker have for interacting with CDER’s staff.
These interactions can help guide biomarker development from the early phase of development through qualification of the biomarker.
Biomarker development can be a long and resource-intensive process. CDER offers multiple opportunities for biomarker developers to engage with FDA staff, which can help to clarify the path and ensure that activities stay on track.
FDA offers biomarker developers interested in seeking qualification three primary opportunities for engagement: the Critical Path Innovation Meeting, the Letter of Support Program, and the Biomarker Qualification Program.
An initial opportunity for biomarker developers, in the early stage of development, to engage FDA is the Critical Path Innovation Meeting. These meetings cover innovative strategies that aim to address a broad range of challenges in drug development. Among these innovations are biomarkers in the early phase of development that are not yet ready for CDER’s Biomarker Qualification Program.
A Critical Path Innovation Meeting offers an opportunity for CDER and the biomarker developer to explore the potential of a proposed biomarker. The meeting is not a forum for obtaining regulatory decisions and it is not a formal part of the biomarker qualification process. Instead, the intent of the meeting is to help developers understand some of the important regulatory questions FDA may have about the proposed biomarker and obtain general advice early in the development process. Topics for meetings held to date are publicly available on the program’s website.
The second opportunity is for biomarker developers with preliminary data to engage with CDER staff through the Letter of Support Program. Biomarker developers can request a Letter of Support from CDER for promising biomarkers that have a potential application in drug development. CDER will evaluate the acceptability of the request and determine whether to issue a letter.
A Letter of Support is meant to enhance the visibility of a biomarker, demonstrate the FDA’s support for the development of the biomarker, encourage collaborative efforts, and stimulate additional studies. The letter briefly describes CDER’s thoughts on the potential value of a promising biomarker across multiple drug development programs and encourages further evaluation.
The letter does not connote qualification of a biomarker and does not endorse a specific biomarker test or device.
CDER has issued 14 Letters of Support for promising biomarkers and these letters are publicly posted on the program’s website.
A third opportunity for biomarker developers to engage with FDA is the Biomarker Qualification Program, which requires a greater level of data than the Letter of Support Program.
The qualification process includes three submission milestones that have increasing levels of evidence required: the Letter of Intent, the Qualification Plan, and the Full Qualification Package. Specifically, at each submission milestone, the qualification requester will receive a formal written determination letter from the FDA accepting or declining the submission. This letter will also include the rationale for the decision, advice, and requests for additional information, as appropriate. Formal written determinations will be publicly available on the FDA website and will be updated on at least a biannual basis.
Throughout the biomarker qualification process requesters can engage the program to seek clarification regarding the content of a determination letter or to obtain additional information about the qualification process, as needed.
After qualification, if additional data is generated for the biomarker that supports an expanded context of use in drug development, the biomarker developer can seek qualification of the biomarker for the expanded COU and may engage with the FDA throughout the new qualification process.
Throughout biomarker development there are opportunities to interact with FDA to enhance the prospects for successful development and qualification of a biomarker for a specified context of use.
This module served as a brief introduction to opportunities for engaging with FDA about qualification during biomarker development through the Critical Path Innovation Meeting, the Letter of Support Program, and the Biomarker Qualification Program.
Learn more: www.fda.gov/BiomarkerQualificationProgram
- Critical Path Innovation Meeting Webpage
View more Videos and Podcasts on FDA’s Biomarker Qualification Program